Company news

GSK plc news in 2023

GSK plc's news releases, calls and decks from 2023, newest first.

View company

Publication of EMTN Suppl.Prospcts

December 20, 2023

Jemperli plus Zejula Trial Meets Endpoint

December 18, 2023

Japan accepts Arexvy filing for at risk adults

December 12, 2023

Jemperli plus chemotherapy EU authorisation

December 11, 2023

GSK publishes provisional 2024 dividend dates

December 4, 2023

GSK announces positive DREAMM-7 headline results

November 27, 2023

GSK receives positive CHMP opinion for momelotinib

November 13, 2023

Jemperli trial meets overall survival endpoint

October 30, 2023

NMPA approves Vocabria+Rekambys in China

October 26, 2023

New data for Arexvy, GSK’s RSV vaccine

October 25, 2023

Jemperli plus chemotherapy positive CHMP opinion

October 16, 2023

Zantac (ranitidine) litigation

October 11, 2023

GSK and Zhifei announce vaccine partnership

October 9, 2023

GSK RSV vaccine for older adults approved in Japan

September 25, 2023

Apretude for PrEP receives EMA approval

September 19, 2023

FDA approves Ojjaara (momelotinib)

September 18, 2023

Momelotinib filing accepted in Japan

September 11, 2023

GSK’s Nucala CRSwNP submission accepted in Japan

September 1, 2023

Shingrix data demonstrate 100% efficacy in China

August 23, 2023

FDA approves new use for Jemperli plus chemo

July 31, 2023

Cabotegravir LA for PrEP receives positive CHMP

July 24, 2023

GSK completes acquisition of BELLUS Health

June 28, 2023

FDA Fast Track for Gonorrhoea Vaccine Candidate

June 27, 2023

Shingrix approved in Japan for adults 18 and over

June 26, 2023

GSK daprodustat gains positive EMA CHMP opinion

June 26, 2023

GSK’s Arexvy recommended by ACIP

June 22, 2023

Season two data for GSK Arexvy RSV OA vaccine

June 21, 2023

Extension of FDA review period for momelotinib

June 16, 2023

EU authorisation of GSK’s RSV vaccine Arexvy

June 7, 2023

GSK receives US FDA file acceptance for Jemperli

June 6, 2023

MenABCWY vaccine preliminary phase III results

May 12, 2023

Statement: Zantac Litigation Update BC Canada

May 12, 2023

US FDA approves GSK’s RSV vaccine for older adults

May 3, 2023

GSK RSV OA vaccine gains positive EMA CHMP opinion

April 27, 2023

EMA validates Jemperli filing for new indication

April 25, 2023

GSK reaches agreement to acquire BELLUS Health Inc

April 18, 2023

Gepotidacin positive phase III data

April 17, 2023

Positive phase III RUBY results for Jemperli

March 28, 2023

Publication of 2023 AGM Notice

March 27, 2023

Positive phase III results for MenABCWY vaccine

March 14, 2023

Nucala NDA accepted for review in China

March 14, 2023

GSK Annual Report 2022 on Form 20-F

March 10, 2023

GSK publishes Annual Report 2022

March 10, 2023

FDA Ad Com votes to support GSK RSV OA vaccine

March 2, 2023

ViiV Healthcare announces Cabenuva positive data

February 23, 2023

NEJM publishes GSK RSV OA vaccine candidate trial

February 16, 2023

Jemperli full FDA approval following GARNET trial

February 10, 2023

Jemperli FDA ODAC positive outcome

February 10, 2023

Daprodustat approved by US FDA for anaemia of CKD

February 2, 2023

Benlysta granted Orphan Drug Designation by US FDA

February 1, 2023

Calls in 2023

Decks in 2023